SG11201407261XA - Oligonucleotide chelate complex methods - Google Patents

Oligonucleotide chelate complex methods

Info

Publication number
SG11201407261XA
SG11201407261XA SG11201407261XA SG11201407261XA SG11201407261XA SG 11201407261X A SG11201407261X A SG 11201407261XA SG 11201407261X A SG11201407261X A SG 11201407261XA SG 11201407261X A SG11201407261X A SG 11201407261XA SG 11201407261X A SG11201407261X A SG 11201407261XA
Authority
SG
Singapore
Prior art keywords
lllll
international
quebec
iii
rule
Prior art date
Application number
SG11201407261XA
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of SG11201407261XA publication Critical patent/SG11201407261XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/170385 A1 (51) International Patent Classification: A61K31/7088 (2006.01) A61K 31/7115 (2006.01) A61K 31/712 (2006.01) A61K31/7125 (2006.01) A61K 31/713 (2006.01) A61P 21/00 (2006.01) A61P 25/28 (2006.01) A61P 3/06 (2006.01) A61P 31/12 (2006.01) A61P 31/14 (2006.01) A61P 31/16 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/CA2013/050378 17 May 2013 (17.05.2013) English English (30) Priority Data: 61/648,694 18 May 2012 (18.05.2012) US (71) Applicant: REPLICOR INC. [CA/CA]; Suite D-101, 6100 Royalmount Avenue, Montreal, Quebec H4P 2R2 (CA). (72) Inventors: BAZINET, Michel; 343 Avenue Brookfield, Montreal, Quebec H3P 2A7 (CA). VAILLANT, Andrew; 74, 11th Street, Roxboro, Quebec H8Y 3E6 (CA). (74) Agent: NORTON ROSE FULBRIGHT CANADA LLP/S.E.N.C.R.L., S.R.L.; Suite 2500, place 1 Ville-Mar- ie, Montreal, Quebec H3B 1R1 (CA). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, [Continued on next page] (54) Title: OLIGONUCLEOTIDE CHELATE COMPLEX METHODS SSii 5 ^ 'X \\ / /f % X (57) Abstract: It is described pharmaceutical compositions and methods for the treatment of viral infections, hypercholester­ olemia, hypertriglyceridemia, Alzheimer's disease, prion disease and Duchene's muscular dystrophy with oligonucleotide chelate complexes. WO 2013/170385 A11 lllll llllllll II llllll III lllll lllll III III III lllll llll llll lllll lllll lllll lllll lllllll llll llll GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H))
SG11201407261XA 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods SG11201407261XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18
PCT/CA2013/050378 WO2013170385A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Publications (1)

Publication Number Publication Date
SG11201407261XA true SG11201407261XA (en) 2014-12-30

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407261XA SG11201407261XA (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex methods

Country Status (37)

Country Link
US (1) US9616083B2 (en)
EP (1) EP2849760B1 (en)
JP (2) JP6294308B2 (en)
KR (1) KR101975915B1 (en)
CN (1) CN104379152B (en)
AR (1) AR091065A1 (en)
AU (1) AU2013262415B2 (en)
BR (1) BR112014028568B1 (en)
CA (1) CA2873526C (en)
CL (1) CL2014003135A1 (en)
CO (1) CO7131388A2 (en)
CR (1) CR20140522A (en)
CU (1) CU20140132A7 (en)
CY (1) CY1122856T1 (en)
DK (1) DK2849760T3 (en)
DO (1) DOP2014000263A (en)
EA (1) EA034799B1 (en)
EC (1) ECSP14027542A (en)
ES (1) ES2767333T3 (en)
HK (1) HK1206259A1 (en)
HR (1) HRP20200045T1 (en)
HU (1) HUE047456T2 (en)
IL (1) IL235402B (en)
IN (1) IN2014DN08982A (en)
LT (1) LT2849760T (en)
MX (1) MX360626B (en)
MY (1) MY168209A (en)
NZ (1) NZ701931A (en)
PH (1) PH12014502484A1 (en)
PL (1) PL2849760T3 (en)
PT (1) PT2849760T (en)
RS (1) RS59914B1 (en)
SG (1) SG11201407261XA (en)
SI (1) SI2849760T1 (en)
TW (1) TWI648288B (en)
WO (1) WO2013170385A1 (en)
ZA (1) ZA201408082B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2203173E (en) 2007-10-26 2016-03-15 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
CA3120918A1 (en) 2012-01-27 2013-08-01 Biomarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
MX361522B (en) 2012-08-30 2018-12-10 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections.
US10745687B2 (en) 2015-04-23 2020-08-18 Geron Corporation Methods of polynucleotide preparation using multivalent cation salt compositions
JP2019507579A (en) 2015-10-28 2019-03-22 クリスパー セラピューティクス アーゲー Materials and methods for the treatment of Duchenne muscular dystrophy
US11534451B2 (en) * 2015-12-23 2022-12-27 Repluca Pty Ltd Nucleic acid oligomers and uses therefor
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE218372T1 (en) * 1993-04-01 2002-06-15 Isis Pharmaceuticals Inc ANTISENSE OLIGONNUCLEOTIDES THAT INTERFER WITH MRNA CAP ACTIVITY AND INHIBIT TRANSLATION
US20020166764A1 (en) * 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
KR101360955B1 (en) * 2002-09-13 2014-02-10 레플리코르 인코포레이티드 non-sequence complementary antiviral oligonucleotides
CN1694959A (en) * 2002-09-13 2005-11-09 雷普利瑟公司 Antiviral oligonucleotides targeting viral families
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
US20090215873A1 (en) 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
AU2007281082A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
CA2717792A1 (en) * 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
EP2408796B1 (en) 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
WO2010138806A2 (en) * 2009-05-28 2010-12-02 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
CA2806616C (en) 2010-08-20 2015-08-11 Replicor Inc. Oligonucleotide chelate complexes

Also Published As

Publication number Publication date
HRP20200045T1 (en) 2020-03-20
IL235402B (en) 2022-01-01
NZ701931A (en) 2016-06-24
CR20140522A (en) 2014-12-10
TW201408689A (en) 2014-03-01
CN104379152A (en) 2015-02-25
AU2013262415A1 (en) 2014-11-27
KR101975915B1 (en) 2019-05-08
IN2014DN08982A (en) 2015-05-22
PH12014502484B1 (en) 2015-01-12
CY1122856T1 (en) 2021-05-05
RS59914B1 (en) 2020-03-31
MY168209A (en) 2018-10-15
ZA201408082B (en) 2015-12-23
ES2767333T3 (en) 2020-06-17
JP2015517503A (en) 2015-06-22
HK1206259A1 (en) 2016-01-08
US9616083B2 (en) 2017-04-11
CL2014003135A1 (en) 2015-01-09
ECSP14027542A (en) 2015-12-31
US20130310445A1 (en) 2013-11-21
MX2014013885A (en) 2015-05-08
KR20150016330A (en) 2015-02-11
DOP2014000263A (en) 2015-01-31
JP2018058853A (en) 2018-04-12
CN104379152B (en) 2018-10-30
EA201401276A1 (en) 2015-04-30
CU20140132A7 (en) 2015-02-26
EP2849760A1 (en) 2015-03-25
DK2849760T3 (en) 2020-02-03
BR112014028568B1 (en) 2022-02-15
CA2873526A1 (en) 2013-11-21
SI2849760T1 (en) 2020-03-31
HUE047456T2 (en) 2020-04-28
PT2849760T (en) 2020-01-24
CA2873526C (en) 2020-08-18
CO7131388A2 (en) 2014-12-01
AR091065A1 (en) 2014-12-30
IL235402A0 (en) 2014-12-31
AU2013262415B2 (en) 2017-06-22
JP6294308B2 (en) 2018-03-14
BR112014028568A2 (en) 2020-06-02
TWI648288B (en) 2019-01-21
EP2849760B1 (en) 2019-10-30
MX360626B (en) 2018-11-12
EP2849760A4 (en) 2015-03-25
WO2013170385A1 (en) 2013-11-21
LT2849760T (en) 2020-04-10
PH12014502484A1 (en) 2015-01-12
EA034799B1 (en) 2020-03-23
PL2849760T3 (en) 2020-05-18

Similar Documents

Publication Publication Date Title
SG11201407261XA (en) Oligonucleotide chelate complex methods
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201806624XA (en) Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201808125RA (en) Methods for solid tumor treatment
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201408261UA (en) Syringe
SG11201407241QA (en) Syringe
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408224SA (en) Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201900904PA (en) Methods for cross coupling
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201803692PA (en) Anti-5t4 antibodies and antibody-drug conjugates
SG11201909837YA (en) Methods for treating lung disorders